Shares of Deciphera Pharmaceuticals Inc. /zigman2/quotes/203556943/composite DCPH -3.11% more than doubled toward a 14-month high in active premarket trading Tuesday, after the biopharmaceutical company said a phase 3 trial of its treatment of gastrointestinal stromal tumors (GIST) achieved its primary endpoint, paving the way for the company to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration. The stock rocketed 125% on volume of over 1.1 million shares ahead of the open, compared with the full-day average volume of about 293,000 shares. The primary endpoint of the study was improved progression free survival (PFS). A key secondary endpoint of objective response rate (ORR) was not statistically significant. The stock has lost 5.0% year to date through Monday, while the iShares Nasdaq Biotechnology ETF /zigman2/quotes/206189322/composite IBB -1.00% has gained 8.0% and the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.23% has climbed 15.0%.